| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及其原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-5.
|
| 2 |
West H. Management of oligometastatic disease in advanced non-small cell lung cancer[J]. Clin Chest Med, 2020, 41(2): 249-258.
|
| 3 |
刘伯轩，陈 成，刘月光，等. 免疫细胞化学对胸腔积液中的肺非小细胞癌分类与恶性间皮瘤的鉴别诊断分析[J]. 临床研究，2020, 28(7): 31-33.
|
| 4 |
Clamon G, Zeitler W, An J, et al. Transformational changes between non-small cell and small cell lung cancer-biological and clinical relevance-a review[J]. Am J Clin Oncol, 2020, 43(9): 670-675.
|
| 5 |
Hosomi Y, Morita S, Sugawara S, et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study[J]. J Clin Oncol, 2020, 38(2): 115-123.
|
| 6 |
Masood A, Kancha RK, Subramanian J. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib[J]. Semin Oncol, 2019, 46(3): 271-283.
|
| 7 |
Yoneda K, Imanishi N, Ichiki Y, et al. Treatment of non-small cell lung cancer with EGFR-mutations[J]. J UOEH, 2019, 41(2): 153-163.
|
| 8 |
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125.
|
| 9 |
Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC[J]. J Thorac Oncol, 2021, 16(5): 740-763.
|
| 10 |
Zhang R, Wang C, Cui K, et al. Prognostic role of computed tomography textural features in early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy[J]. Cancer Manag Res, 2019, 11(2): 9921-9930.
|
| 11 |
惠福海. 非小细胞肺癌患者肺癌组织和血浆中EGFR外显子19、21的基因突变研究[M]. 沈阳：沈阳药科大学，2010: 74-77.
|
| 12 |
张百红，岳红云. 实体瘤疗效评价标准简介[J]. 国际肿瘤学杂志，2016, 43(11): 845-847.
|
| 13 |
Bílek O, Holánek M, Berkovcová J, et al. Uncommon EGFR mutations in non-small cell lung cancer and their impact on the treatment[J]. Klin Onkol, 2019, 32(2): 6-12.
|
| 14 |
Hsu PC, Jablons DM, Yang CT, et al. Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (yap) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC)[J]. Int J Mol Sci, 2019, 20(15): 3821-3829.
|
| 15 |
Nagano T, Tachihara M, Nishimura Y. Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer[J]. Curr Cancer Drug Targets, 2019, 19(8): 595-630.
|
| 16 |
Xia WY, Feng W, Zhang CC, et al. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review[J]. Transl Lung Cancer Res, 2020, 9(5): 2120-2136.
|
| 17 |
Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725-737.
|
| 18 |
Planchard D. Adjuvant osimertinib in EGFR-mutated non-small-cell lung cancer [J]. N Engl J Med, 2020, 383(18): 1780-1782.
|
| 19 |
Aguiar PN Jr, Haaland B, Park W, et al. Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(8): 1080-1084.
|
| 20 |
贺新爱，马 馨，郜娜娜. 奥希替尼脂质体治疗NSCLC小鼠的疗效及对其免疫功能、生存时间的影响[J]. 临床肺科杂志，2018, 23(4): 613-616.
|
| 21 |
侯志华，魏 晗，魏红艳，等. 奥希替尼联合颅脑放疗治疗非小细胞肺癌脑转移效果观察[J]. 河北医科大学学报，2020, 41(6): 14-17.
|
| 22 |
Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib[J]. JAMA Oncol, 2018, 4(11): 1527-1534.
|
| 23 |
Taniguchi H, Yamada T, Wang R, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells[J]. Nat Commun, 2019, 10(1): 259-264.
|
| 24 |
Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase Ⅱ trial (KCSG-LU15-09)[J]. J Clin Oncol, 2020, 38(5): 488-495.
|
| 25 |
Mezquita L, Varga A, Planchard D. Safety of osimertinib in EGFR-mutated non-small cell lung cancer[J]. Expert Opin Drug Saf, 2018, 17(12): 1239-1248.
|
| 26 |
Ramalingam SS, Yang JC, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(9): 841-849.
|